Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer

Liposomal Doxorubicin-based Regimen Improves Outcomes in Platinum-sensitive Ovarian Cancer
Second-line treatment with a combination of bevacizumab plus the chemotherapies carboplatin and pegylated liposomal doxorubicin may significantly improve the outcomes of platinum-sensitive ovarian cancer patients, compared to standard treatment, findings from a Phase 3 trial suggest. Women who received this experimental combination in the ENGOT-ov18 trial (NCT01837251) lived significantly longer without disease progression and experienced extended overall survival than those on standard bevacizumab, carboplatin, and gemcitabine, all without impairing quality of life. The findings were detailed in a study, "Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial," published in The Lancet Oncology. Current treatment for women with ovarian cancer who responded to first-line platinum-based chemotherapy consists of a combination of bevacizumab, a therapy marketed as Avastin by Roche, among other brand names, that prevents blood vessels from growing in cancers, plus the chemotherapeu
Subscribe or to access all post and page content.